Johnson & Johnson reports two-year ICOTYDE data showing sustained clearance in high-impact psoriasis
Johnson & Johnson reported two-year data for ICOTYDE, showing sustained skin clearance in high-impact psoriasis. Clear or almost clear skin increased from 57% to 70% by Week 112. Complete clearance rates were 60% for scalp, 89% for genital, and 63% for hands/feet. Nail psoriasis improved, with mNAPSI scores rising from 33% to 71%. Safety findings were consistent with no new signals. ICOTYDE is approved for plaque psoriasis and is being studied for other conditions.
How this was made
The 30-second read
Why it matters
The data show sustained skin clearance and high response rates across difficult‑to‑treat sites, suggesting a strong therapeutic profile.
Market read
Positive trial data could lift JNJ's stock and benefit peers in the dermatology space.
What to watch
Potential competition from other IL‑23 inhibitors could limit market share.
Background
The article reports new Phase 3 trial outcomes for ICOTYDE, an IL‑23 receptor antagonist developed by Johnson & Johnson for moderate‑to‑severe plaque psoriasis and related inflammatory diseases.
Ticker impact
Johnson & Johnson released two-year ICOTYDE Phase 3 data showing sustained clearance in high‑impact psoriasis up to Week 112.
likely upward pressure as market prices in the favorable trial results
Phase 3 data are material for a large pharma company; no new safety concerns were reported.
Market effects
strengthens outlook for the broader dermatology and immunology drug segment.
U.S. and European markets may see modest gains in biotech stocks.
reinforces confidence in late‑stage psoriasis therapies worldwide.
Counterpoint
Investors may question commercial viability if pricing or reimbursement remains uncertain.
Key entities
- companyJohnson & Johnson
US healthcare conglomerate reporting the trial results.
- drugICOTYDE
Oral peptide IL‑23 receptor blocker under investigation.
